N@N

49.85% Of All NASDAQ Trading Monday Was Short Selling. ENMD, HLTH, CERS, VSAT, NRGN, CLRT Highest % Of Daily Trading Volume Sh

^{Published on 2009-10-05 15:13:02, Last Modified on 2010-12-22 14:51:44 - WOPRAI}
 

October 6, 2009 / M2 PRESSWIRE / BUYINS.NET, www.buyins.net, has reviewed the NASDAQ Daily Short Volume Report for Monday, October 5th, 2009 and come to the following statistical conclusions. There were 6,643 stocks with daily short volume reported and total NASDAQ trading volume of 1,609,489,933 shares. Total Daily Short Volume was 802,391,315 shares. 49.85% of all trading on the NASDAQ Monday was short selling. The chart below highlights 6 stocks that had unusually high percentages of their total daily trading volume attributed to short sales. EntreMed (NASDAQ: ENMD), HTLH Corp (NASDAQ: HLTH), Cerus Corp (NASDAQ: CERS), ViaSat (NASDAQ: VSAT), Neurogen (NASDAQ: NRGN) and Clarient (NASDAQ: CLRT). To access SqueezeTrigger Prices ahead of potential short squeezes beginning, visit http://www.buyins.net.

DATE SYMBOL SHORT VOLUME TOTAL VOLUME MARKET PERCENT

20091005 ENMD 65,013 74,077 Q 87.76%

20091005 HLTH 116,036 140,776 Q 82.43%

20091005 CERS 54,241 66,520 Q 81.54%

20091005 VSAT 78,884 97,037 Q 81.29%

20091005 NRGN 100,934 124,249 Q 81.24%

20091005 CLRT 64,204 79,104 Q 81.16%

In late October 2008 the SEC updated Regulation SHO requiring that all short sellers must locate, borrow and deliver any shares they have shorted, no exceptions, by T+3 settlement date. If not, a buy-in must be forced by the broker dealer that the short seller transacted through by the opening of the market on T+4. Since a company first appears on the naked short list when short sellers have been failing to deliver for 5 consecutive trading days, stocks should theoretically never be on the naked short list again. BUYINS.NET will monitor the exchangesa� naked short lists daily and issue an alert and notify the SEC and FINRA should short sellers fail to deliver on any short sales.

Reg SHO Rule 204 (i) requires brokers to deliver shares on long and short sales of publicly traded equity securities by settlement date, (ii) continues to require brokers to close-out fails to deliver by the beginning of trading on T+4 for short sales and T+6 for long sales, (iii) precludes clearing brokers and their introducing brokers from selling short a security, other than on a pre-borrowed basis, if a fail to deliver in that security is not timely closed out until the fail is closed out and that close-out transaction settles, (iv) allows clearing brokers to allocate fails to introducing brokers and (v) continues to permit brokers to rely upon pre-fail credit to satisfy Rule 204's close-out requirement to avoid the pre-borrow requirements when a fail at a clearing broker has not been closed out. However, the SEC liberalized certain of these provisions in several regards. For example, permanent Rule 204 now allows a broker to close-out a fail on a long sale by borrowing the security, whereas Rule 204T had only permitted closing out long fails by buying-in, which should alleviate some of the buy-in risk for investors that experience long fails. Similar relief was extended to close-outs for market maker fails, so that a fail from a bona fide market making transaction (including short and long fails) can now be closed out by the beginning of trading on T+6 by borrowing the security. Further, Rule 204 now permits a broker to borrow securities to obtain pre-fail credit for early close-outs, whereas temporary Rule 204T only permitted pre-fail credit to be obtained by purchases of securities.

The SEC refused requests to extend the close-out deadline for fails to deliver to the close of business on the close-out deadline, choosing instead to retain the requirement that all fails be closed out by the beginning of trading on the applicable close-out deadline. The Commission also rejected requests for a fail to deliver exception that would have provided an exception from the close-out requirements if a clearing broker's fail position was below a certain amount but said that it would continue to monitor whether a de minimis or odd lot exception could be warranted.

EntreMed, Inc. (NASDAQ: ENMD), a clinical-stage pharmaceutical company, develops therapeutic candidates primarily for the treatment of cancer and inflammation. The companya�s clinical development products include ENMD-2076, an Aurora A and angiogenic kinase inhibitor with potent activity against Aurora A and multiple tyrosine kinases linked to cancer and inflammatory diseases; used to treat tumor regression in various xenograft models, such as breast, colon, and leukemia; an activity towards ex vivo-treated human leukemia patient cells; and in Phase I clinical studies to treat solid tumors and multiple myeloma. Its clinical development products also include MKC-1, an oral cell-cycle inhibitor with activity against the mTOR pathway, which is in multiple Phase II clinical trials for metastatic breast, non-small cell lung, leukemia, pancreatic, ovarian/endometrial, and solid cancer tumors; ENMD-1198, an antimitotic agent that is in Phase I studies that induces cell cycle arrest and apoptosis in tumor cells; and Panzem, a Phase I clinical trial candidate for the treatment of rheumatoid arthritis. The company has license agreements with Childrena�s Hospital Medical Center Corporation and Celgene Corporation. EntreMed, Inc. was founded in 1991 and is headquartered in Rockville, Maryland.

HLTH Corporation (NASDAQ: HLTH), through its principal subsidiary, WebMD Health Corp., provides health information services to consumers, physicians, healthcare professionals, employers, and health plans in the United States. The company offers various services comprising online healthcare information, decision-support applications, and communications services. Its consumer portals enable consumers to obtain detailed information on a particular disease or condition, locate physicians, store individual healthcare information, assess their personal health status, receive periodic e-newsletters and alerts on topics of individual interest, and to participate in online communities with peers and experts. The companya�s public portals help physicians and healthcare professionals to access clinical reference sources, stay abreast of the clinical information, learn about new treatment options, earn continuing medical education and continuing education credit, and communicate with peers. Its private portals enable employers and health plans to provide their employees and plan members with personalized health and benefit information, and decision-support technology. The companya�s online services also comprise e-detailing promotion and physician recruitment services for pharmaceutical, medical device, and healthcare companies. In addition, HLTH Corporation offers offline health publications, such as WebMD the Magazine, a consumer publication; and The WebMD Little Blue Book, a physician directory. The company was formerly known as Emdeon Corporation and changed its name to HLTH Corporation in May 2007. HLTH Corporation was founded in 1995 and is headquartered in Elmwood Park, New Jersey.

Cerus Corporation (NASDAQ: CERS), a biomedical products company, engages in the development and commercialization of the INTERCEPT Blood System. The companya�s INTERCEPT system is designed to inactivate blood-borne pathogens in donated blood components intended for transfusion. It markets the INTERCEPT system for platelets and plasma primarily in Europe, the Russian Federation, and the Middle East. The company is also developing INTERCEPT Blood System for red blood cells or red blood cell system, which is designed to inactivate blood-borne pathogens in donated red blood cells for transfusion. It has collaboration agreements with Baxter International, Inc., BioOne Corporation, and Laboratorios Grifols S.A., as well as the United States Armed Forces. The company was founded in 1991 and is based in Concord, California.

ViaSat, Inc. (NASDAQ: VSAT) engages in the production of satellite and other wireless communications and networking systems for government and commercial customers worldwide. The companya�s Government Systems segment develops and produces data links, including multifunctional information distribution system (MIDS) terminals, and MIDS joint tactical radio system development and unmanned vehicle technologies; information security and assurance products and services, which enable military and government users to communicate secure information over secure and non-secure networks; and government satellite communication systems and products, including UHF DAMA satellite communications products consisting of modems, terminals, and network control systems, and broadband solutions for government customers. Its Commercial Networks segment provides satellite communication and other wireless communications equipment solutions, including consumer broadband products and solutions to customers based on DOCSIS or DVB-RCS-based technology; mobile broadband products and systems for airborne, maritime, and ground mobile broadband applications; enterprise very small aperture terminal networks products; satellite networking systems design and technology development; and antenna systems for commercial and defense applications and customers. It also provides commercial satellite network engineering, gateway construction, and remote terminal manufacturing for various interactive communications services. The companya�s Satellite Services segment offers managed broadband services that provide terrestrial and satellite connections through a call center and network management operation for everyday enterprise networking or backup protection for primary networks; mobile broadband services that include network management services; and wholesale bandwidth services. The company was founded in 1986 and is headquartered in Carlsbad, California.

Neurogen Corporation (NASDAQ: NRGN) engages in the development of new small molecule drugs for psychiatric and neurological disorders. The companya�s clinical development programs include aplindore, which is in Phase II clinical trials for the treatment of Parkinsona�s disease and restless legs syndrome; and MK 2295, a VR1 receptor antagonist that is in preclinical development for the treatment of pain and cough. It has a collaboration and licensing agreement with Merck Sharp & Dohme Limited to research, develop, and commercialize small molecule medicines that work by targeting the VR1 receptor; and a licensing agreement with Wyeth Pharmaceuticals to acquire worldwide rights to aplindore. The company was founded in 1987 and is based in Branford, Connecticut.

Clarient, Inc. (NASDAQ: CLRT) provides oncology diagnostics services to community pathologists, biopharmaceutical companies, and researchers in the United States. It provides various cancer diagnostic and consultative services, including technical laboratory services and professional interpretation, such as reports and analyses through its Internet-based application, PATHSiTE; and commercial services to biopharmaceutical companies and other research organizations, ranging from drug discovery assistance to the development of directed diagnostics through clinical trials. The company also offers hematopathology testing for leukemia and lymphoma. It has collaboration agreements with Natural Selection, Inc. to use its genomic mathematic capability to supplement proteomic mathematic capability to help develop novel cancer markers, as well as with Prediction Sciences, Inc. to commercialize a novel breast cancer test. The company was formerly known as ChromaVision Medical Systems, Inc. and changed its name to Clarient, Inc. in 2005. Clarient was founded in 1993 and is headquartered in Aliso Viejo, California.

About BUYINS.NET

WWW.BUYINS.NET is a service designed to help bonafide shareholders of publicly traded US companies fight naked short selling. Naked short selling is the illegal act of short selling a stock when no affirmative determination has been made to locate shares of the stock to hypothecate in connection with the short sale. Buyins.net has built a proprietary database that uses Threshold list feeds from NASDAQ, AMEX and NYSE to generate detailed and useful information to combat the naked short selling problem. For the first time, actual trade by trade data is available to the public that shows the attempted size, actual size, price and average value of short sales in stocks that have been shorted and naked shorted. This information is valuable in determining the precise point at which short sellers go out-of-the-money and start losing on their short and naked short trades.

BUYINS.NET has built a massive database that collects, analyzes and publishes a proprietary SqueezeTrigger for each stock that has been shorted. The SqueezeTrigger database of nearly 2,650,000,000 short sale transactions goes back to January 1, 2005 and calculates the exact price at which the Total Short Interest is short in each stock. This data was never before available prior to January 1, 2005 because the Self Regulatory Organizations (primary exchanges) guarded it aggressively. After the SEC passed Regulation SHO, exchanges were forced to allow data processors like Buyins.net to access the data.

The SqueezeTrigger database collects individual short trade data on over 7,000 NYSE, AMEX and NASDAQ stocks and general short trade data on nearly 8,000 OTCBB and PINKSHEET stocks. Each month the database grows by approximately 50,000,000 short sale transactions and provides investors with the knowledge necessary to time when to buy and sell stocks with outstanding short positions. By tracking the size and price of each montha�s short transactions, BUYINS.NET provides institutions, traders, analysts, journalists and individual investors the exact price point where short sellers start losing money and a short squeeze can begin.

All material herein was prepared by BUYINS.NET, based upon information believed to be reliable. The information contained herein is not guaranteed by BUYINS.NET to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. Occassionally companies or third parties pay $995 per month to purchase data for information provided in monthly reports. The data service can be cancelled at any time. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. BUYINS.NET is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. BUYINS.NET will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.

BUYINS.NET and SQUEEZETRIGGER are intended for use by stock market professionals. As a member, visitor, or user of any kind, you accept full responsibilities for your investment and trading actions. The contents of BUYINS.NET, including but not limited to all implied or expressed views, opinions, teachings, data, graphs, opinions, or otherwise are not predictions, warranty, or endorsements of any kind. Please seek stock market advice from the proper securities professional, or investment advisor. By visiting BUYINS.NET or using any data or services, you agree to assume full responsibility for the decisions or actions that you undertake. BUYINS.NET, LLC, its owner(s), operators, employees, partners, affiliates, advertisers, information providers and any other associated person or entity, shall under no circumstances be held liable to the user and/or any third party for loss or damages of any kind, including but not limited to trading losses, lost trading opportunity, direct, indirect, consequential, special, incidental, or punitive damages. As a user, you agree that any damages collected shall not exceed the amount paid to BUYINS.NET and/or its owners. As a website user, you agree that any and all legal matters of any kind are to be reviewed and handled in their entirety within the State of California only. By using the services of this website, you are consenting to the terms as outlined, and forfeit all legal jurisdictions in any other State. Past performance is not a guarantee of future outcomes. Any and all examples are hypothetical and should not be considered a guarantee or endorsement of such trading activity. BUYINS.NET does not take responsibility for problems of any kind, including but not limited to issues with operations, data accuracy or completeness, contacting issues, technical issues, and timeliness. BUYINS.NET places great integrity on the data collected and distributed. This information is deemed reliable, but not guaranteed. All information and data is provided "as is" without warranty or guarantee of any kind.

Please seek investment and/or trading advice, council, information or services from a securities professional. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and BUYINS.NET undertakes no obligation to update such statements.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the SEC.

Contact: Thomas Ronk, CEO www.BUYINS.net +1-800-715-9999 Tom@buyins.net